Company creates U.S. subsidiary and adds Dr. Jeffrey Jeddeloh as VP of Business Development, Commercial Strategy, Dr. Stephen Macevicz as VP of IP and Dr. Christine Peponnet as VP of Technology Development. PARIS and CAMBRIDGE, Mass., Nov 8, 2018 – DNA Script, the global leader in the development of enzymatic DNA synthesis, today announced the creation... Read more
DNA Script’s approach achieves parity with conventional chemical synthesis — and is poised to quickly surpass the current gold standard in speed, efficacy and length for commercial DNA synthesis. October 02, 2018 01:40 PM Pacific Daylight Time SAN FRANCISCO, Calif.–(BUSINESS WIRE)–DNA Script, the global leader in the development of enzymatic DNA synthesis, today announced that... Read more
September 12, 2017 06:00 AM Pacific Daylight Time PARIS–(BUSINESS WIRE)–Synthetic DNA manufacturer DNA Script has today announced a Series A fundraising of 11 million euros ($13 million) led by Illumina Ventures with additional investments from M Ventures, the corporate venture arm of Merck KGaA, Darmstadt, Germany, plus existing investors Sofinnova Partners, Kurma Partners, and Idinvest... Read more